Project Orbis Nears 30 Approvals In Oncology; Could China Be Added?
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.
You may also be interested in...
The goal is for EMA officials to better understand the process, but becoming an official member still may prove difficult because of the EMA regulatory scheme.
Oncology Center of Excellence Deputy Director Paul Kluetz talks about what might make a drug a good candidate for a Project Frontrunner-type development program and how sponsors might benefit from FDA’s experience with OCE’s first Project Pragmatica pilot.
OCE Director Richard Pazdur says idea for the latest initiative stemmed from a clinical trial in lung cancer that he thought only needed to measure the impact on overall survival.